Potential biomarkers of coagulopathy and disease severity in COVID-19

potential biomarkers of coagulopathy and disease severity in covid 19

Sumary of Potential biomarkers of coagulopathy and disease severity in COVID-19:

  • Not only do patients display impaired fibrinolysis, but also platelet aggregation, inflammation, and microthrombi.
  • Understanding this pathology could help healthcare workers treat these symptoms, often associated with low survival levels in severe COVID-19 patients.
  • Study: Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients.
  • To further explore this phenomenon, scientists have investigated the presence of specific biomarkers in hospitalized COVID-19 patients.
  • A preprint version of the study is available on the medRxiv* server while the article undergoes peer review.
  • The study The study included 63 patients showing positive PCR test results for COVID-19 and 43 healthy/non-infected individuals as controls.
  • Forty-seven of the infected group had progressed to severe COVID-19, requiring admission to the ICU and showing symptoms such as shock, respiratory distress, and multiorgan dysfunction.
  • The remaining patients were hospitalized, but not severe, although one did require mechanical ventilation.

Want to know more click here go to source.

From -


Site Language

Popular Posts


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.